HK1117532A1 - Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors - Google Patents

Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors

Info

Publication number
HK1117532A1
HK1117532A1 HK08111437.0A HK08111437A HK1117532A1 HK 1117532 A1 HK1117532 A1 HK 1117532A1 HK 08111437 A HK08111437 A HK 08111437A HK 1117532 A1 HK1117532 A1 HK 1117532A1
Authority
HK
Hong Kong
Prior art keywords
compound
reuptake inhibitors
isotopologues
serotonin reuptake
novel deuterated
Prior art date
Application number
HK08111437.0A
Other languages
English (en)
Inventor
Roger Tung
Original Assignee
Concert Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals Inc filed Critical Concert Pharmaceuticals Inc
Publication of HK1117532A1 publication Critical patent/HK1117532A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
HK08111437.0A 2005-07-29 2008-10-16 Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors HK1117532A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70407305P 2005-07-29 2005-07-29
PCT/US2006/029599 WO2007016431A2 (en) 2005-07-29 2006-07-28 Novel benzo [d] [1,3]-dioxol derivatives

Publications (1)

Publication Number Publication Date
HK1117532A1 true HK1117532A1 (en) 2009-01-16

Family

ID=37709249

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08111437.0A HK1117532A1 (en) 2005-07-29 2008-10-16 Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors

Country Status (13)

Country Link
US (5) US20080287495A1 (xx)
EP (1) EP1910322B1 (xx)
JP (1) JP5301991B2 (xx)
KR (1) KR101380190B1 (xx)
CN (1) CN101273024A (xx)
AU (1) AU2006275595B2 (xx)
BR (1) BRPI0615973A2 (xx)
CA (1) CA2616383C (xx)
EA (1) EA014432B1 (xx)
ES (1) ES2396365T3 (xx)
HK (1) HK1117532A1 (xx)
WO (1) WO2007016431A2 (xx)
ZA (1) ZA200800785B (xx)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5301991B2 (ja) * 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
EP1948646A2 (en) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
JP5038392B2 (ja) * 2006-04-03 2012-10-03 エフ．ホフマン−ラ ロシュ アーゲー 鏡像異性的に富化した環式β−アリール又はヘテロアリールカルボン酸の調製方法
WO2008127300A2 (en) * 2006-10-23 2008-10-23 Concert Pharmaceuticals Inc. Oxazolidinone derivatives and methods of use
WO2008109175A1 (en) * 2007-03-07 2008-09-12 Concert Pharmaceuticals, Inc. Deuterated piperazine derivatives as anti-anginal compounds
JP4642134B2 (ja) * 2007-05-01 2011-03-02 コンサート ファーマシューティカルズ インコーポレイテッド ナフチル（エチル）アセトアミド
CN102964302B (zh) * 2007-05-01 2015-10-21 康塞特医药品公司 吗啡烷化合物
LT3825306T (lt) 2007-05-01 2023-08-10 Sun Pharmaceutical Industries, Inc. Morfinano junginiai
US20080312247A1 (en) * 2007-06-13 2008-12-18 Auspex Pharmaceuticals, Inc. Substituted piperazines
CA2698808A1 (en) * 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
AU2009270936B2 (en) * 2008-07-15 2014-12-18 Theracos, Inc. Deuterated benzylbenzene derivatives and methods of use
WO2010010141A1 (en) * 2008-07-25 2010-01-28 Boehringer Ingelheim International Gmbh Pramipexole for treating cardiomyopathy
US20100093721A1 (en) * 2008-10-13 2010-04-15 Barbay J Kent PHENYL AND HETEROARYL SUBSTITUTED THIENO[2,3-d]PYRIMIDINES AND THEIR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS
US9045453B2 (en) 2008-11-14 2015-06-02 Concert Pharmaceuticals, Inc. Substituted dioxopiperidinyl phthalimide derivatives
JP5647615B2 (ja) * 2008-11-14 2015-01-07 コンサート ファーマシューティカルズ インコーポレイテッド 置換ジオキソピペリジニルフタルイミド誘導体
WO2010077730A2 (en) * 2008-12-09 2010-07-08 Auspex Pharmaceutical, Inc Indanone inhibitors of acetylcholinesterase
WO2010075086A2 (en) * 2008-12-15 2010-07-01 Auspex Pharmaceuticals, Inc. Pyrrolidinone inhibitors of pde-4
BR112012009784A2 (pt) 2009-10-26 2016-05-17 Otsuka Pharma Co Ltd composto benzazepínico
WO2011159920A1 (en) * 2010-06-17 2011-12-22 Concert Pharmaceuticals, Inc. [5,6]-dihydro-2h-pyran-2-one derivatives
PE20141113A1 (es) 2011-06-20 2014-09-25 Lundbeck & Co As H 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia
CN104039777B (zh) * 2012-01-31 2016-03-02 卫材R&D管理有限公司 帕罗西汀衍生物
WO2013116480A1 (en) 2012-02-03 2013-08-08 Selectx Pharmaceuticals, Inc. 4,6-substituted 2,5-dideoxystreptamine aminoglycoside antibiotics
EP2687854A1 (en) * 2012-07-19 2014-01-22 Chiron AS Test kit for the quantitative determination of narcotic drugs
EP2922838B1 (en) 2012-10-22 2018-03-14 Concert Pharmaceuticals Inc. Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} .
AR094054A1 (es) * 2012-12-19 2015-07-08 H Lundbeck As 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma
SG10201806965XA (en) 2013-03-13 2018-09-27 Boston Biomedical Inc 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer
CA2916653C (en) * 2013-06-27 2017-07-18 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
CN104059030B (zh) 2014-05-30 2016-05-04 镇江圣安医药有限公司 [(苯硫烷基)-苯基]哌嗪的衍生物及其药物组合物和用途
IL282156B (en) 2014-07-29 2022-07-01 Shenzhen Hightide Biopharmaceutical Ltd Salts of berberic acid, salts of ursodeoxycholic acid and their combinations, methods for their preparation and their uses
US10089505B1 (en) 2015-09-29 2018-10-02 Amazon Technologies, Inc. Inventory tracking using RFID
US10037449B1 (en) 2015-09-29 2018-07-31 Amazon Technologies, Inc. Inventory tracking using RFID
ES2849560T3 (es) 2016-05-04 2021-08-19 Genoscience Pharma Sas Derivados de 2,4-diamino-quinolina sustituidos para su uso en el tratamiento de enfermedades proliferativas
EP3456328A4 (en) 2016-05-10 2020-02-26 Shenzhen Hightide Biopharmaceutical., Ltd. COMPOSITION AND USE AND PHARMACEUTICAL PREPARATION THEREOF
MX2018015452A (es) 2016-12-15 2020-02-10 Soc Des Produits Nestle S A Star Composiciones y metodos que modulan fosforo o las enzimas en un aminal de compañia.
CN108864077B (zh) 2017-05-12 2020-05-22 深圳君圣泰生物技术有限公司 小檗碱有机酸盐的固体形式及其制备方法
CN109134432B (zh) * 2017-06-15 2021-06-11 北京君科华元医药科技有限公司 氘代抗抑郁药物
EP3675860B1 (en) 2017-08-28 2023-03-08 Zhihong, Chen Substituted pyrimidines, pharmaceutical compositions and therapeutic methods thereof
CN107970243B (zh) * 2017-10-30 2020-07-28 江苏理工学院 一种去甲氯氮平的新用途
MX2021004517A (es) 2018-11-01 2021-11-04 Lynk Pharmaceuticals Co Ltd Inhibidores de cinasa de janus 1 triciclicos y composiciones y metodos de los mismos.
CN113056457A (zh) 2018-12-03 2021-06-29 H.隆德贝克有限公司 4-((1R,3S)-6-氯-3-苯基-2,3-二氢-1H-茚-1-基)-1,2,2-三甲基哌嗪和4-((1R,3S)-6-氯-3-(苯基-d5)-2,3-二氢-1H-茚-1-基)-2,2-二甲基-1-(甲基-d3)哌嗪的前药
WO2020146845A1 (en) 2019-01-11 2020-07-16 University Of Rochester Compositions and methods for treating prostate cancer with enzalutamide and an inhibitor of monoamin oxidase a
KR20210141461A (ko) 2019-02-01 2021-11-23 캔웰 바이오테크 리미티드 이미다조퀴놀린 아민 유도체, 약제학적 조성물, 이의 용도
EP3921322A4 (en) 2019-02-07 2022-07-20 Canwell Biotech Limited PHOSPHORUS-IMIDAZOCHINOLINE-AMINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF
CN110283156B (zh) * 2019-07-29 2020-06-30 河北省农林科学院经济作物研究所 从刺五加中提取的新型降血脂化合物
EP4037717A1 (en) 2019-10-04 2022-08-10 Seagen Inc. Camptothecin peptide conjugates
WO2021216325A1 (en) 2020-04-22 2021-10-28 University Of Rochester Compositions and methods for treating metabolic and cardiovascular diseases
EP4358957A1 (en) 2021-06-22 2024-05-01 Dana-Farber Cancer Institute, Inc. (1h-pyrrolo[2,3-b]pyridin-1-yl)pyrimidin-2-yl-amino-phenyl--acrylamide inhibitors of egfr for use in the treatment of brain tumors

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
GB8430581D0 (en) 1984-12-04 1985-01-09 Ferrosan As Treatment
AU1966188A (en) * 1987-08-07 1989-03-09 Mallinckrodt, Inc. Diagnostic or radiotherapeutic composition comprising a hydrogen containing compound
AU707748B2 (en) * 1994-03-25 1999-07-22 Isotechnika Inc. Enhancement of the efficacy of drugs by deuteration
US6221335B1 (en) * 1994-03-25 2001-04-24 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US5597826A (en) * 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
AU3108097A (en) * 1997-06-10 1998-12-30 Synthon B.V. 4-phenylpiperidine compounds
US6440710B1 (en) * 1998-12-10 2002-08-27 The Scripps Research Institute Antibody-catalyzed deuteration, tritiation, dedeuteration or detritiation of carbonyl compounds
DK1104760T3 (da) * 1999-12-03 2003-06-30 Pfizer Prod Inc Sulfamoylheteroarylpyrazolforbindelser som anti-inflammatoriske/analgetiske midler
EP1134290A3 (en) * 2000-03-14 2004-01-02 Pfizer Products Inc. Pharmacophore models for the identification of the CYP2D6 inhibitory potency of selective serotonin reuptake inhibitors
US6436938B1 (en) * 2001-01-22 2002-08-20 Pfizer Inc. Combination treatment for depression
US6720003B2 (en) * 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
TW200413273A (en) * 2002-11-15 2004-08-01 Wako Pure Chem Ind Ltd Heavy hydrogenation method of heterocyclic rings
JP5301991B2 (ja) * 2005-07-29 2013-09-25 コンサート ファーマシューティカルズ インコーポレイテッド 新規なベンゾ［ｄ］［１，３］−ジオキソール誘導体
US20080033011A1 (en) * 2005-07-29 2008-02-07 Concert Pharmaceuticals Inc. Novel benzo[d][1,3]-dioxol derivatives
EP1934201A1 (en) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
EP1948646A2 (en) * 2005-11-14 2008-07-30 Auspex Pharmaceuticals Inc. Substituted phenylpiperidines with serotoninergic activity and enhanced therapeutic properties
US7750168B2 (en) * 2006-02-10 2010-07-06 Sigma-Aldrich Co. Stabilized deuteroborane-tetrahydrofuran complex
JO2630B1 (en) 2006-04-13 2012-06-17 نوفارتيس ايه جي Organic compounds
CA2661404A1 (en) * 2006-09-05 2008-03-13 Schering Corporation Pharmaceutical combinations for lipid management and in the treatment of atherosclerosis and hepatic steatosis
CA2698808A1 (en) * 2007-09-13 2009-03-19 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof

Also Published As

Publication number Publication date
US20080287495A1 (en) 2008-11-20
EP1910322A2 (en) 2008-04-16
EA014432B1 (ru) 2010-12-30
BRPI0615973A2 (pt) 2011-05-31
US20150196544A1 (en) 2015-07-16
KR20080039949A (ko) 2008-05-07
US20140018390A1 (en) 2014-01-16
KR101380190B1 (ko) 2014-04-11
US8450492B2 (en) 2013-05-28
EA200800490A1 (ru) 2008-08-29
AU2006275595A1 (en) 2007-02-08
JP5301991B2 (ja) 2013-09-25
WO2007016431A3 (en) 2007-07-12
US7678914B2 (en) 2010-03-16
WO2007016431A2 (en) 2007-02-08
ES2396365T3 (es) 2013-02-21
CN101273024A (zh) 2008-09-24
US20070191432A1 (en) 2007-08-16
JP2009502963A (ja) 2009-01-29
CA2616383C (en) 2015-06-09
EP1910322B1 (en) 2012-09-05
ZA200800785B (en) 2009-01-28
AU2006275595B2 (en) 2012-08-16
CA2616383A1 (en) 2007-02-08
US20100222589A1 (en) 2010-09-02
EP1910322A4 (en) 2010-09-22

Similar Documents

Publication Publication Date Title
HK1117532A1 (en) Novel deuterated benzo [d][1,3]-dioxol derivatives as serotonin reuptake inhibitors
BR0308339A (pt) Indazóis substituìdos com uma atividade anticancerosa
TW200503705A (en) 3-amino chroman and 2-amino tetralin derivatives
ATE466002T1 (de) Substituierte benzo (d) isoaxol-3-yl-amin- verbindungen als analgetika
WO2006073610A3 (en) Novel bicyclic heterocyclic compounds, process for their preparation and compositions containing them
MX2009004108A (es) Compuestos de tetrahidropirrolopiracina sustituidos teniendo afinidad al canal kcnq2/3 k+ y su uso en farmacos.
MX2009005455A (es) (r)-n-estereoisomeros de analogos de 7,8-saturados-4,5 epoxi-morfinano.
ZA200508390B (en) Compositions and methods for the therapy of inflammatory bowel disease
BRPI0923786C8 (pt) compostos 5,6-dihidro-6-fenilbenzo(f) isoquinolina-2- amina substituidos e composições farmacêuticas compreendendo ditos compostos
WO2006058201A3 (en) Heterocyclic and bicyclic compounds, compositions and methods
MX2007007919A (es) Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp).
WO2004042353A8 (en) Identifying therapeutic compounds based on their physical-chemical properties
ATE433966T1 (de) Methylendipiperidinderivate
BRPI0408817A (pt) composto, processo de preparação do mesmo, composição farmacêutico, e, utilização de um composto
ATE427983T1 (de) Bariumsulfat, verfahren zu dessen herstellung und dessen verwendung
MX2009006034A (es) Anticuerpos antagonistas contra ephb3.
WO2007120621A3 (en) Nonel 1,2,3,4-tetrahydroquinoline derivatives
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives
RS20070095A (xx) Alkiliden-tetrahidronaftalen derivati, postupak njihove proizvodnje i njihova upotreba kao anti-inflamatornih sredstava
DK1895017T3 (da) Anvendelse af A33-antigener og JAM-IT
ATE446299T1 (de) Verfahren zur herstellung von 7-ethyl-10- hydroxycamptothecin
ATE431396T1 (de) Für hcv-infektion geeignete zusammensetzungen und verfahren
HK1112928A1 (en) Cspcna isoform modifications and uses thereof
BRPI0416672A (pt) método de produção de uma composição granular contendo lecitina e composição granular contendo lecitina
MX2007010769A (es) Compuestos de quinolina como agonistas de receptor 5-ht4.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20160728